Takeshi Yuasa - Concepedia

Author

Takeshi Yuasa

Japanese Foundation For Cancer Research ORCID

Also Known As

Satoshi Yanagisawa, T Yuasa, T. Yuasa, T.Y Yuasa, TAKESHI YUASA, Takeshi YUASA, Takeshi Yuasa, Takeshi yuasa, Yuasa T, Yuasa Takeshi

528

Publications

8.5K

Citations

H-Index

186

Concepts

All Affiliations

Japanese Foundation For Cancer Research Kyoto University Dana-Farber Cancer Institute Aarhus University Hospital Akita University

About

Takeshi Yuasa is an author at Japanese Foundation For Cancer Research specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	81	3.4K
2	Engineering	12	13	243
3	Health Sciences	6	6	211
4	Natural Sciences	3	3	118
5	Language Studies	1	1	20

Takeshi Yuasa

167

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini, European Urology UrologySurgical OncologyGenitourinary CancerMedicineCytoreductive Nephrectomy	2014	467
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Jenny J. Ko, Wanling Xie, Nils Kroeger, The Lancet Oncology First-line Targeted TherapyUrologyPopulation-based StudyGenitourinary CancerMedicine	2015	364
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival Shaan Dudani, Guillermo de Velasco, J. Connor Wells, JAMA Network Open	2021	273
Fission yeast condensin complex: essential roles of non-SMC subunits for condensation and Cdc2 phosphorylation of Cut3/SMC4 Takashi Sutani, Takeshi Yuasa, Takeshi Tomonaga, Genes & Development	1999	267
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Shinya Kimura, Haruna Naito, Hidekazu Segawa, Blood	2005	243
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria Nils Kroeger, Wanling Xie, Jae‐Lyn Lee, Cancer	2013	231
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations Laurence Albigès, A. Ari Hakimi, Wanling Xie, Journal of Clinical Oncology	2016	211
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer Masaki Nogawa, Takeshi Yuasa, Shinya Kimura, Journal of Clinical Investigation	2005	185
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials D.Y.C. Heng, Toni K. Choueiri, Brian I. Rini, Annals of Oncology UrologyGenitourinary CancerEligibility CriteriaMedicineCancer Management	2013	144
Cytotoxic effects of γδ T cells expanded <i>ex vivo</i> by a third generation bisphosphonate for cancer immunotherapy Kiyoshi Sato, Shinya Kimura, Hidekazu Segawa, International Journal of Cancer	2005	141

Page 1